开云app官网登录入口网页版-官方正版

#侵袭性淋巴瘤#

0篇内容 | 939人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2219728, encodeId=ba872219e2869, content=<a href='/topic/show?id=c1a4e76382' target=_blank style='color:#2F92EE;'>#G-CSF#</a> <a href='/topic/show?id=c12d2e010a1' target=_blank style='color:#2F92EE;'>#侵袭性淋巴瘤#</a> <a href='/topic/show?id=532311e791ac' target=_blank style='color:#2F92EE;'>#依托泊苷联合阿糖胞苷#</a>, objectTitle=依托泊苷+阿糖胞苷+ G-CSF联合干细胞动员治疗复发或难治性淋巴瘤的疗效和安全性, objectType=article, longId=838751, objectId=ae34838e51ca, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240714/1720949097955_5579292.jpg, objectUrl=/article/show_article.do?id=ae34838e51ca, replyNumber=0, likeNumber=24, createdTime=2024-08-12, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ae34838e51ca, moduleTitle=依托泊苷+阿糖胞苷+ G-CSF联合干细胞动员治疗复发或难治性淋巴瘤的疗效和安全性, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ae34838e51ca)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2203754, encodeId=f5392203e54fe, content=<a href='/topic/show?id=c5795004ece' target=_blank style='color:#2F92EE;'>#弥漫性大B细胞淋巴瘤#</a> <a href='/topic/show?id=3b4765888dd' target=_blank style='color:#2F92EE;'>#液体活检#</a> <a href='/topic/show?id=c12d2e010a1' target=_blank style='color:#2F92EE;'>#侵袭性淋巴瘤#</a>, objectTitle=【Trends Mol Med】侵袭性淋巴瘤液体活检新进展:迈向风险调适治疗, objectType=article, longId=825012, objectId=09888250126b, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240509/1715263548368_5579292.png, objectUrl=/article/show_article.do?id=09888250126b, replyNumber=0, likeNumber=103, createdTime=2024-05-09, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=09888250126b, moduleTitle=【Trends Mol Med】侵袭性淋巴瘤液体活检新进展:迈向风险调适治疗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=09888250126b)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2174289, encodeId=b1e221e42899b, content=<a href='/topic/show?id=bde45355068' target=_blank style='color:#2F92EE;'>#慢性淋巴细胞白血病#</a> <a href='/topic/show?id=c12d2e010a1' target=_blank style='color:#2F92EE;'>#侵袭性淋巴瘤#</a> <a href='/topic/show?id=f6ff154653c' target=_blank style='color:#2F92EE;'>#Richter综合征#</a> <a href='/topic/show?id=e555603625e' target=_blank style='color:#2F92EE;'>#替雷利珠单抗#</a> <a href='/topic/show?id=2c90650e5b1' target=_blank style='color:#2F92EE;'>#泽布替尼#</a>, objectTitle=Nat Med：替雷利珠单抗联合泽布替尼治疗Richter综合征的2期RT1研究, objectType=article, longId=804447, objectId=0c3180444e40, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20230326/1679868111251_4754896.png, objectUrl=/article/show_article.do?id=0c3180444e40, replyNumber=0, likeNumber=101, createdTime=2023-12-11, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=0c3180444e40, moduleTitle=Nat Med：替雷利珠单抗联合泽布替尼治疗Richter综合征的2期RT1研究, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=0c3180444e40)], followStatus=false, userIsMember=false, type=null, lengthMark=0)] 风湿免疫小助手

侵袭性淋巴瘤

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#G-CSF# #侵袭性淋巴瘤# #依托泊苷联合阿糖胞苷#

依托泊苷+阿糖胞苷+ G-CSF联合干细胞动员治疗复发或难治性淋巴瘤的疗效和安全性

2024-08-12发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#弥漫性大B细胞淋巴瘤# #液体活检# #侵袭性淋巴瘤#

【Trends Mol Med】侵袭性淋巴瘤液体活检新进展:迈向风险调适治疗

2024-05-09发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#慢性淋巴细胞白血病# #侵袭性淋巴瘤# #Richter综合征# #替雷利珠单抗# #泽布替尼#

Nat Med：替雷利珠单抗联合泽布替尼治疗Richter综合征的2期RT1研究

2023-12-11发表于上海

科室
- - 订阅+
  - 更多科室
工具
服务